IOLCP Q3 FY26 Earnings Call Transcript Released: Revenue Up 10.9%, PAT Guidance for Q4
IOLCP reported Q3 FY26 revenue of ₹580 crore, up 10.9% YoY, with EBITDA at ₹62.6 crore, up 22.8%. For 9MFY26, revenue was ₹1,699.6 crore, up 9.6%. The company declared an interim dividend of 50%. Management expects 10-15% revenue growth and 15-20% profit growth in FY27. Q4 FY26 revenue is projected at ₹600 crore.
The announcement pertains to the release of an earnings call transcript, which provides detailed financial performance and future outlook. While it confirms positive financial trends and provides guidance, it does not announce a new, significant corporate action or event that would have an immediate high impact.
The company reported year-on-year growth in revenue and EBITDA for Q3 FY26 and the nine-month period. The declaration of an interim dividend and positive outlook for the next financial year further contribute to a positive sentiment.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has released the transcript of its earnings conference call held on February 12, 2026, following the declaration of financial results for the quarter and nine months ended December 31, 2025.
During the third quarter of FY26, the company reported a revenue from operations of ₹580 crore, a 10.9% increase compared to ₹523 crore in the corresponding quarter of the previous year. EBITDA for the quarter stood at ₹62.6 crore, up by 22.8% from ₹50.9 crore in Q3 FY25. PBT before exceptional items rose by 39.3% to ₹38.8 crore from ₹27.8 crore, with EBITDA margins improving to 10.7% from 9.7% and PBT margins increasing to 6.6% from 5.3% year-on-year. An exceptional item of ₹11.2 crore was reported, pertaining to a provision related to new labor laws, which is non-recurring.
For the nine-month period ended December 2025, revenue from operations was ₹1,699.6 crore, an increase of 9.6% from ₹1,551.4 crore in the previous year. EBITDA for this period was ₹196.1 crore, up by 24.8% from ₹157.1 crore. PBT before exceptional items grew by 34.2% to ₹124.8 crore from ₹93 crore. EBITDA margins for the nine months improved to 11.4% from 10%, and PBT margins increased to 7.3% from 5.9%.
The company's Board of Directors declared an interim dividend of 50% per equity share for FY25-26. Management highlighted growth in the pharmaceutical segment, particularly in non-ibuprofen APIs, and a stable performance in the chemicals business. The company expects a minimum 10% to 15% revenue growth and 15% to 20% bottom-line growth for FY27. The company anticipates reaching ₹600 crore in revenue for Q4 FY26 with improved margins.
Key discussions during the call included drivers for margin expansion, such as increased capacity utilization and operational efficiencies. The company is focusing on expanding its footprint in regulated markets, increasing the share of high-value non-ibuprofen APIs, and strengthening R&D capabilities. Backward integration initiatives and a growing product pipeline are also key strategic priorities. Capex for FY27 is expected to be around ₹150-200 crore, similar to previous years, with 60% allocated for growth and 40% for infrastructure development and automation.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.